| Literature DB >> 19442434 |
Fu-Yue Zeng1, Jimmy Cui, Lingling Liu, Taosheng Chen.
Abstract
Patients with alveolar rhabdomyosarcoma (ARMS) have poorer response to conventional chemotherapy and lower survival rates than those with embryonal RMS (ERMS). By high-throughput screening, we identified camptothecin as an ARMS-selective inhibitor. Camptothecin more efficiently inhibited proliferation and induced apoptosis in Rh30 (ARMS) than RD (ERMS) cells. Ectopic expression of the PAX3-FKHR (PF) fusion protein in RD cells significantly increased sensitivity, whereas siRNA knockdown of PF decreased sensitivity of Rh30 cells to camptothecin. The sensitization required a transcriptionally active PF, and camptothecin downregulated levels of PF protein. These findings suggest that it is feasible to develop agents that preferentially block the growth of ARMS. 2009 Elsevier Ireland Ltd.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19442434 PMCID： PMC2739888 DOI： 10.1016/j.canlet.2009.04.016
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679